Diagnosing IBD

Evaluation of the Quantum Blue® rapid test for faecal calprotectin

The Quantum Blue method was a suitable screening test for excluding inflammatory bowel disease. It may be of value to laboratories wishing to offer calprotectin but who do not have sufficient numbers to warrant ELISA methodology or in ‘one stop’ gastrointestinal clinics where an immediate result is required.

Wassell, et al. (2011) Annals of Clinical Biochemistry
Fecal calprotectin is equally sensitive in Crohn’s disease affecting the small bowel and colon

Levels and sensitivities of fCal are equal in patients with colonic and small bowel CD. Due to its high sensitivity and negative predictive value, fCal is a useful marker to rule out CD and select patients for endoscopy.

Jensen, et al. (2011) Scandinavian Journal of Gastroenterology
Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study

In patients with abdominal discomfort, fecal calprotectin is a useful non-invasive marker to identify clinically significant findings of the gastrointestinal tract, irrespective of age.

Manz, et al. (2012) BMC Gastroenterology
Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care

Correct use of the test and adherence to usage/referral protocols are likely to lead to fewer referrals to secondary care and consequently fewer investigations with potential cost savings.

Pavlidis, et al. (2013) Scandinavian Journal of Gastroenterology
Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease

Overall accuracy for differentiating IBD from IBS or “other colitis” was the best for Quantum Blue® Calprotectin (97%/91%).

Jang, et al. (2016) Intestinal Research
Evaluation of a faecal calprotectin care pathway for use in primary care

The care pathway for FC in primary care had a 97% NPV and a 40% PPV. This was better than GP clinical judgement alone and doubled the PPV compared with the standard FC cut-off.

Turvill, et al. (2016) Primary Health Care Research and Development
Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply?

FC is beneficial in distinguishing between functional GI conditions (IBS) and organic disease (IBD). In those with IBD, a 250 μg/g cut-off aids in determining clinical disease activity.

Dhaliwal, et al. (2015) Frontline Gastroenterology
Ruling out IBD: estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin

The use of F-calprotectin as a screening test substantially could reduce the number of invasive measurements necessary in the diagnostic work-up of patients with suspected IBD, as well as the associated costs

Mindemark, et. al. (2012) Clinical Biochemistry